Free Trial
NASDAQ:ABVX

ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis

$12.35
+0.07 (+0.57%)
(As of 09/6/2024 ET)
Today's Range
$11.89
$12.38
50-Day Range
$10.85
$13.75
52-Week Range
$7.99
$17.02
Volume
76,768 shs
Average Volume
83,327 shs
Market Capitalization
$777.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.50

ABIVAX Société Anonyme MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
195.5% Upside
$36.50 Price Target
Short Interest
Healthy
0.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.98) to ($2.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.00 out of 5 stars

Medical Sector

540th out of 910 stocks

Pharmaceutical Preparations Industry

249th out of 426 stocks

ABVX stock logo

About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABVX Stock Price History

ABVX Stock News Headlines

Analysts Set ABIVAX Société Anonyme (NASDAQ:ABVX) PT at $36.50
Why billionaires are wiring money to abandoned towns
A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution.
Abivax SA ADR (ABVX)
Abivax Provides Operational and Key Program Update
Why billionaires are wiring money to abandoned towns
A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution.
ABVX ABIVAX Société Anonyme
Abivax SA ADR ABVX
Abivax S.A. ADR
ABIVAX Société Anonyme (ABVX.PA)
Abivax SA ABVX
See More Headlines
Receive ABVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
9/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABVX
Previous Symbol
NASDAQ:ABVX
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.50
High Stock Price Target
$50.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+195.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.37 per share

Miscellaneous

Free Float
N/A
Market Cap
$777.17 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Marc M. P. de Garidel M.B.A. (Age 66)
    CEO & Interim Chair of Board
    Comp: $862.25k
  • Dr. Philippe Pouletty M.D. (Age 66)
    Ph.D., Founder & Director
  • Mr. Didier Blondel (Age 60)
    EVP, CFO & Board Secretary
  • Mr. Didier Scherrer Ph.D. (Age 54)
    Chief Scientific Officer
  • Mr. Patrick Malloy
    Senior Vice President of Investor Relations
  • Ms. Ida Hatoum (Age 49)
    Chief People Officer
  • Mr. Pierre Courteille M.B.A. (Age 55)
    Chief Business Officer
  • Mr. Jerome Denis Ph.D.
    Executive Vice President of Process Development & Manufacturing
  • Mr. Sheldon Sloan M.B.E. (Age 65)
    M.D., Chief Medical Officer
  • Mr. Michael Ferguson B.S. (Age 46)
    M.B.A., Chief Commercial Officer

ABVX Stock Analysis - Frequently Asked Questions

How have ABVX shares performed this year?

ABIVAX Société Anonyme's stock was trading at $10.70 at the beginning of 2024. Since then, ABVX stock has increased by 15.4% and is now trading at $12.35.
View the best growth stocks for 2024 here
.

When did ABIVAX Société Anonyme IPO?

ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share.

Who are ABIVAX Société Anonyme's major shareholders?

Top institutional shareholders of ABIVAX Société Anonyme include Great Point Partners LLC (3.93%), Nantahala Capital Management LLC (1.57%), HighVista Strategies LLC (0.08%) and Sandia Investment Management LP (0.01%).

How do I buy shares of ABIVAX Société Anonyme?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABVX) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners